Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 96Pancreatic Neoplasms 83Carcinoma, Non-Small-Cell Lung 79Ovarian Neoplasms 52Fallopian Tube Neoplasms 47Triple Negative Breast Neoplasms 42Lung Neoplasms 32Neoplasm Metastasis 27Squamous Cell Carcinoma of Head and Neck 23Neoplasms 19Breast Neoplasms, Male 18Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Melanoma 16Brenner Tumor 16Stomach Neoplasms 15Carcinoma, Ovarian Epithelial 15Esophageal Neoplasms 13Adenocarcinoma of Lung 13Inflammatory Breast Neoplasms 11Cholangiocarcinoma 10Adenocarcinoma, Bronchiolo-Alveolar 9Urinary Bladder Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 8Oropharyngeal Neoplasms 8Carcinoma, Transitional Cell 8Adenocarcinoma Of Esophagus 8Mouth Neoplasms 7Esophageal Squamous Cell Carcinoma 7Colorectal Neoplasms 7

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1Oxaliplatin 1HMPL-013 1Docetaxel 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gastric Cancer Adenocarcinoma Metastatic × Taxes × Clear all
NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
68 enrolled
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡